Because regardless of price it is currently too risky to buy now without FDA approvals. If things do not go to plan with Tali milestones and approvals Akili can wash their hands of Tali at very minimal cost to them.
A small portion of the $50mill best case scenario for Tali.
To buy Tali now, Akili would need to stump up $50mill and then go through the approvals phase with risk of failure ontop of the $50mill purchase. That itself would cost more than $50mill for a lemon.
They are getting Tali FDA approved for less $ and risk as what it would cost if they owned it.
There will be a moment when they see that Tali is the real deal and will compliment them and pounce.
Because regardless of price it is currently too risky to buy now...
Add TD1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.295M | |||
| Open | High | Low | Value | Volume |
| 0.1¢ | 0.1¢ | 0.1¢ | $54 | 53.61K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 23619429 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 35609707 | 16 |
View Market Depth
| Last trade - 14.52pm 23/08/2024 (20 minute delay) ? |
| TD1 (ASX) Chart |